摘要
转移性乳腺癌(MBC)患者普遍使用蒽环类和紫杉烷类药物治疗,但部分患者对紫杉烷类药物过敏,还有一些患者在治疗后对紫杉烷类产生耐药性,病症会在短期内迅速复发。对于这些患者,很难找到其他有效治疗方案。伊沙匹隆作为新一代微管抑制剂类抗肿瘤药物在对蒽环类和紫杉烷类药物耐药的MBC患者的治疗中作用显著,现对伊沙匹隆的药理学和临床方面的研究进行综述。
Generally, anthracyclines and taxanes are applied to treat metastatic breast cancer (MBC) as chemotherapeutic agents. However, some patients are over-sensitive to taxanes, or experience rapid relapse due to resistance to taxanes, for whom, anthracyclines and taxanes have poor therapentic efficacy. Fortunately, ixabepilone, a novel microtubules inhibitor, exerts great effects on MBC patients who are resistant to anthracyclines and taxanes. In this article, we reviewed the pharmacology of ixabepilone and its progress in clinical research.
出处
《中华老年多器官疾病杂志》
2013年第10期792-796,共5页
Chinese Journal of Multiple Organ Diseases in the Elderly
基金
陕西省社发攻关课题省级基金(2012K18-01-08)
关键词
伊沙匹隆
转移性乳腺癌
微管抑制剂
埃博霉素
ixabepilone
metastatic breast cancer
microtubules inhibitor
epothilone